{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:47:16Z","timestamp":1768283236395,"version":"3.49.0"},"reference-count":79,"publisher":"Becaris Publishing Limited","issue":"2","funder":[{"name":"Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>To analyze the cost\u2013effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS).<jats:bold>Methods:<\/jats:bold>A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed.<jats:bold>Results:<\/jats:bold>CladT was the dominant treatment, with lower costs (-74,741 \u20ac [95% CI: -67,247; -85,661 \u20ac]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF.<jats:bold>Conclusion:<\/jats:bold>CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.<\/jats:p>","DOI":"10.2217\/cer-2022-0193","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:37:05Z","timestamp":1674815825000},"source":"Crossref","is-referenced-by-count":2,"title":["Cost\u2013effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain"],"prefix":"10.57264","volume":"12","author":[{"given":"Ricardo","family":"Ginestal","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, Neurology Department, C\/ Prof Mart\u00edn Lagos, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rubio-Terr\u00e9s","sequence":"additional","affiliation":[{"name":"HEALTH VALUE, HE Department, C\/ Virgen de Ar\u00e1nzazu, 21, 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Dur\u00e1n","family":"Mor\u00e1n","sequence":"additional","affiliation":[{"name":"Merck, SLU, C\/ Mar\u00eda de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Rubio-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"HEALTH VALUE, HE Department, C\/ Virgen de Ar\u00e1nzazu, 21, 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-2376","authenticated-orcid":false,"given":"Heidi De","family":"Los Santos","sequence":"additional","affiliation":[{"name":"Merck, SLU, C\/ Mar\u00eda de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck, SLU, C\/ Mar\u00eda de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"S\u00e1nchez-Magro","sequence":"additional","affiliation":[{"name":"Merck, SLU, C\/ Mar\u00eda de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban X","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96\u2013120 (2018).","journal-title":"Mult. Scler."},{"key":"e_1_3_4_4_2","unstructured":"MSSSI: Ministerio de Sanidad Servicios Sociales e Igualdad. Estrategia en Enfermedades Neurodegenerativas del Sistema Nacional de Salud (2016). Available from: www.msps.es\/organizacion\/sns\/planCalidadSNS\/pdf\/Est_Neurodegenerativas_APROBADA_C_INTERTERRITORIAL.pdf (Accessed December 2021)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.nrl.2014.04.016","article-title":"Estudio epidemiol\u00f3gico de la esclerosis m\u00faltiple en La Rioja","volume":"30","author":"B\u00e1rtulos M","year":"2015","unstructured":"B\u00e1rtulos M, Marzo ME, Estrella LA, Bravo Y. Estudio epidemiol\u00f3gico de la esclerosis m\u00faltiple en La Rioja. Neurolog\u00eda 30, 552\u2013560 (2015).","journal-title":"Neurolog\u00eda"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ane.12363","article-title":"Long-term epidemiology of multiple sclerosis in the Northern Seville District","volume":"132","author":"Izquierdo G","year":"2015","unstructured":"Izquierdo G, Venegas A, Sanabria C, Navarro G. Long-term epidemiology of multiple sclerosis in the Northern Seville District. Acta Neurol. Scand. 132, 111\u2013117 (2015).","journal-title":"Acta Neurol. Scand."},{"key":"e_1_3_4_7_2","first-page":"396","article-title":"Prevalencia de la esclerosis m\u00faltiple en la Regi\u00f3n de Murcia","volume":"62","author":"Carre\u00f3n-Guarnizo E","year":"2016","unstructured":"Carre\u00f3n-Guarnizo E, Andreu-Rein\u00f3n E, Cerd\u00e1n-S\u00e1nchez M Prevalencia de la esclerosis m\u00faltiple en la Regi\u00f3n de Murcia. Rev. Neurol. 62, 396\u2013402 (2016).","journal-title":"Rev. Neurol."},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2019.05.022","article-title":"Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain","volume":"33","author":"Perez-Carmona N","year":"2019","unstructured":"Perez-Carmona N, Gimenez-Martinez J, Borrego-Honrubia C, Sempere AP. Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain. Mult. Scler. Relat. Disord. 33, 78\u201381 (2019).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"e_1_3_4_9_2","first-page":"19","article-title":"Prevalencia de la esclerosis m\u00faltiple en la ciudad de Ourense, Galicia, noroeste de la Pen\u00ednsula Ib\u00e9rica [The prevalence of multiple sclerosis in the city of Ourense, Galicia, in the north-west of the Iberian Peninsula]","volume":"71","author":"Garc\u00eda-Est\u00e9vez DA","year":"2020","unstructured":"Garc\u00eda-Est\u00e9vez DA, Fraga-Gonz\u00e1lez C, Ramos-Pacho ME, L\u00f3pez-D\u00edaz LM, Pardo-Parrado M, Prieto JM. Prevalencia de la esclerosis m\u00faltiple en la ciudad de Ourense, Galicia, noroeste de la Pen\u00ednsula Ib\u00e9rica [The prevalence of multiple sclerosis in the city of Ourense, Galicia, in the north-west of the Iberian Peninsula]. Rev. Neurol. 71, 19\u201325 (2020).","journal-title":"Rev. Neurol."},{"issue":"2","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1352458517708672","article-title":"The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain","volume":"23","author":"Oreja-Guevara C","year":"2017","unstructured":"Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J. The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Mult. Scler. J. 23(2S), 166\u2013178 (2017).","journal-title":"Mult. Scler. J."},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14737167.2017.1358617","article-title":"Estimate of the cost of multiple sclerosis in Spain by literature review","volume":"17","author":"Fern\u00e1ndez O","year":"2017","unstructured":"Fern\u00e1ndez O, Calleja-Hern\u00e1ndez MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, P\u00e9rez-Alc\u00e1ntara F. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev. Pharmacoecon. Outcomes Res. 17, 321\u2013333 (2017).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker BG","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112, 133\u2013146 (1989).","journal-title":"Brain"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux C","year":"2006","unstructured":"Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 129, 606\u2013616 (2006).","journal-title":"Brain"},{"key":"e_1_3_4_14_2","unstructured":"Tecfidera 120 mg\/240 mg c\u00e1psulas duras gastrorresistentes. Ficha t\u00e9cnica o Resumen de Caracter\u00edsticas del Producto. 20 de septiembre de 2018. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/113837001\/FT_113837001.pdf (Accessed 14 December 2021)."},{"key":"e_1_3_4_15_2","unstructured":"Mavenclad 10 mg comprimidos. Ficha t\u00e9cnica o Resumen de Caracter\u00edsticas del Producto. 22 de agosto de 2017. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1171212001\/FT_1171212001.pdf (Accessed 14 December 2021)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14737167.2019.1635014","article-title":"Cost\u2013effectiveness of Cladribine tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain","volume":"20","author":"Poveda JL","year":"2020","unstructured":"Poveda JL, Trillo JL, Rubio-Terr\u00e9s C, Rubio-Rodr\u00edguez D, Polanco A, Torres C. Cost\u2013effectiveness of Cladribine tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. Expert Rev. Pharmacoecon. Outcomes Res. 20, 295\u2013303 (2020).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"18","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/WNL.98.18_supplement.1373","article-title":"MSBase Study Group. Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: Results from the MSBase Registry (P12-4.003)","volume":"98","author":"Butzkueven H","year":"2022","unstructured":"Butzkueven H, Spelman T, Ozakbas S MSBase Study Group. Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: Results from the MSBase Registry (P12-4.003). Neurology 98(Suppl. 18), 1373 (2022).","journal-title":"Neurology"},{"key":"e_1_3_4_18_2","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Therapeutic Review. Comparative clinical and Cost\u2013effectiveness of drug therapies for relapsing-remitting multiple sclerosis. Canadian Agency for Drugs and Technologies in Health Canada (CADTH Therapeutic Review vol.1 no. 2b). Available from: http:\/\/www.cadth.ca\/media\/pdf\/TR0004_RRMS_ScienceReport_e.pdf (Accessed 30 August 2021)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/1352458512439119","article-title":"BC MS Clinic Neurologists. Natural, innate improvements in multiple sclerosis disability","volume":"18","author":"Tremlett H","year":"2012","unstructured":"Tremlett H, Zhu F, Petkau J, Oger J, Zhao Y. BC MS Clinic Neurologists. Natural, innate improvements in multiple sclerosis disability. Mult. Scler. 18, 1412\u20131421 (2012).","journal-title":"Mult. Scler."},{"key":"e_1_3_4_20_2","unstructured":"Couto E Hamidi V Ringerike T Odgaard-Jensen J Harboe I Klemp M. Medicines Used for Multiple Sclerosis \u2013 a Health Technology Assessment. Report from the Norwegian Institute of Public Health No. 2016-23. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH) Norway (2016)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5144\/0256-4947.2017.433","article-title":"Cost\u2013effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia","volume":"37","author":"Alsaqa'aby MF","year":"2017","unstructured":"Alsaqa'aby MF, Vaidya V, Khreis N, Khairallah TA, Al-Jedai AH. Cost\u2013effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Ann. Saudi Med. 37, 433\u2013443 (2017).","journal-title":"Ann. Saudi Med."},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1212\/NXI.0000000000000878","article-title":"Cladribine vs other drugs in MS: merging randomized trial with real-life data","volume":"7","author":"Signori A","year":"2020","unstructured":"Signori A, Sacc\u00e0 F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol. Neuroimmunol. Neuroinflamm. 7, e878 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"e_1_3_4_23_2","unstructured":"TreeAge Pro Healthcare 2021. TreeAge Software LCC MA USA. Available from: www.treeage.com (Accessed 18 December 2021)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui MK","year":"2017","unstructured":"Siddiqui MK, Khurana IS, Budhia S Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr. Med. Res. Opin. 34, 1361\u20131371 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_4_25_2","volume-title":"Methods for Quantitative Synthesis in Medicine.","author":"Petitti DB","year":"1994","unstructured":"Petitti DB. Meta-Analysis, Decision Analysis, and Cost\u2013effectiveness Analysis. Methods for Quantitative Synthesis in Medicine. Oxford University Press, NY, USA (1994)."},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3111\/13696998.2016.1164174","article-title":"The Cost\u2013effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada","volume":"19","author":"Su W","year":"2016","unstructured":"Su W, Kansal A, Vicente C, Deniz B, Sarda S. The Cost\u2013effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. J. Med. Econ. 19, 718\u2013727 (2016).","journal-title":"J. Med. Econ."},{"key":"e_1_3_4_27_2","unstructured":"INE. Tablas de mortalidad por a\u00f1o sexo edad y funciones. Resultados nacionales por comunidades aut\u00f3nomas y provincias. Available from: www.ine.es\/jaxiT3\/Datos.htm?t=27150#!tabs-grafico (Accessed 18 June 2021)."},{"key":"e_1_3_4_28_2","unstructured":"Estrategia en Enfermedades Neurodegenerativas del Sistema Nacional de Salud. Estrategia aprobada por el Consejo Interterritorial el Sistema Nacional de Salud el 13 de abril de 2016. Ministerio de Sanidad Servicios Sociales e Igualdad. Madrid (2016). Available from: www.mscbs.gob.es\/organizacion\/sns\/planCalidadSNS\/pdf\/Est_Neurodegenerativas_ APROBADA_C_INTERTERRITORIAL.pdf (Accessed 18 June 2021)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1524-4733.2004.75007.x","article-title":"Cost\u2013effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis","volume":"7","author":"Prosser LA","year":"2004","unstructured":"Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost\u2013effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 7, 554\u2013568 (2004).","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_4_30_2","first-page":"160","article-title":"Direct costs of relapses in patients with relapsing-remitting multiple sclerosis","volume":"1","author":"Casado V","year":"2021","unstructured":"Casado V, Bonaventura I, Brieva L Direct costs of relapses in patients with relapsing-remitting multiple sclerosis. Neurol. Persp. 1(3), 160\u2013169 (2021).","journal-title":"Neurol. Persp."},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1472-6963-6-143","article-title":"Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability","volume":"6","author":"Casado V","year":"2006","unstructured":"Casado V, Mart\u00ednez-Y\u00e9lamos S, Mart\u00ednez-Y\u00e9lamos A Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv. Res. 6, 143 (2006).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_4_32_2","unstructured":"BotPlus 2.0. Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF) (2021). Available from: www.portalfarma.com (Accessed 18 June 2021)."},{"key":"e_1_3_4_33_2","unstructured":"Real Decreto-ley 8\/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. BOE N\u00b0 126 Lunes 24 de mayo de 2010: 45070."},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni G","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416\u2013426 (2010).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni G","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult. Scler. 24, 1594\u20131604 (2018).","journal-title":"Mult. Scler."},{"key":"e_1_3_4_36_2","volume-title":"ECTRIMS 2021 Virtual Congress.","author":"Giovannoni G","year":"2021","unstructured":"Giovannoni G, Leist T, Aydemir A, Verdun E. on behalf of the CLASSIC-MS Steering Committee. Long-term efficacy for patients receiving cladribine tablets in CLARITY\/CLARITY extension: primary results from 9-15 years of follow-up in the CLASSIC-MS study. Presented at: ECTRIMS 2021 Virtual Congress. (13-15 October 2021)."},{"issue":"5","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","volume":"28","author":"Gold R","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult. Scler. 28(5), 801\u2013816 (2022).","journal-title":"Mult. Scler."},{"key":"e_1_3_4_38_2","unstructured":"CLARITY Extension Study. ClinicalTrials.gov Identifier: NCT00641537 (2020). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00641537?term=cladribine+clarity&draw=2&rank=1 (Accessed: 17 December 2021)."},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00115-018-0498-0","article-title":"Cladribin-Tabletten: Orale Immuntherapie der schubf\u00f6rmigen Multiplen Sklerose mit kurzen, j\u00e4hrlichen Behandlungsphasen [Cladribine tablets: Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]","volume":"89","author":"Meuth SG","year":"2018","unstructured":"Meuth SG, Ruck T, Aktas O, Hartung HP. Cladribin-Tabletten: Orale Immuntherapie der schubf\u00f6rmigen Multiplen Sklerose mit kurzen, j\u00e4hrlichen Behandlungsphasen [Cladribine tablets: Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Nervenarzt 89, 895\u2013907 (2018).","journal-title":"Nervenarzt"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician's review","volume":"11","author":"Giovannoni G","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician's review. Neurol. Ther. 11, 571\u2013595 (2022).","journal-title":"Neurol. Ther."},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox RJ","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087\u20131097 (2012).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold R","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098\u20131107 (2012).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook S","year":"2019","unstructured":"Cook S, Leist T, Comi G Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult. Scler. Relat. Disord. 29, 157\u2013167 (2019).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"102566","DOI":"10.1016\/j.msard.2020.102566","article-title":"Safety of dimethyl fumarate for multiple sclerosis: a systematic review and meta-analysis","volume":"46","author":"Liang G","year":"2020","unstructured":"Liang G, Chai J, Ng HS, Tremlett H. Safety of dimethyl fumarate for multiple sclerosis: a systematic review and meta-analysis. Mult. Scler. Relat. Disord. 46, 102566 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"e_1_3_4_45_2","unstructured":"A Safety and Efficacy Study of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY). ClinicalTrials.gov Identifier: NCT00213135 (2014). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00213135?term=cladribine++clarity&draw=2&rank=3 (Accessed 17 December 2021)."},{"key":"e_1_3_4_46_2","unstructured":"Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM). ClinicalTrials.gov Identifier: NCT00451451 (2015a). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00451451 (Accessed 17 December 2021)."},{"key":"e_1_3_4_47_2","unstructured":"Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE). ClinicalTrials.gov Identifier: NCT00420212 (2015b). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00420212 (Accessed 17 December 2021)."},{"key":"e_1_3_4_48_2","first-page":"127","article-title":"Hipotiroidismo: implicaciones cl\u00ednicas y econ\u00f3micas en un \u00e1rea de salud","volume":"20","author":"De Luis D","year":"2003","unstructured":"De Luis D, Gonz\u00e1lez JL, Aller R, Gonz\u00e1lez M, Cuellar L, Terroba MC. Hipotiroidismo: implicaciones cl\u00ednicas y econ\u00f3micas en un \u00e1rea de salud. An. Med. Intern. 20, 127\u2013133 (2003).","journal-title":"An. Med. Intern."},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1157\/13092984","article-title":"Estudio de costes de la gripe","volume":"38","author":"Bad\u00eda X","year":"2006","unstructured":"Bad\u00eda X, Roset M, Franc\u00e9s JM, \u00c1lvarez C, Rubio Terr\u00e9s C. Estudio de costes de la gripe. Aten Primaria 38, 260\u2013267 (2006).","journal-title":"Aten Primaria"},{"key":"e_1_3_4_50_2","unstructured":"Resoluci\u00f3n del director general del Servicio de salud de modificaci\u00f3n del anexo I de la Orden de la Consejer\u00eda de Salud y Consumo de 22 de diciembre de 2006. BOIB N\u00b0 89 1 d julio de 2014."},{"key":"e_1_3_4_51_2","first-page":"98","article-title":"Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients","volume":"25","author":"Llibre-Codina JM","year":"2007","unstructured":"Llibre-Codina JM, Casado-G\u00f3mez MA, S\u00e1nchez-de la Rosa R Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients. Enferm. Infecc. Microbiol. Clin. 25, 98\u2013107 (2007).","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"issue":"8","key":"e_1_3_4_52_2","first-page":"290","article-title":"Cost of arterial hypertension according to levels of morbidity in primary care setting","volume":"133","author":"Sicras-Mainar A","year":"2009","unstructured":"Sicras-Mainar A, Navarro-Artieda R. Cost of arterial hypertension according to levels of morbidity in primary care setting. Med. Clin. (Barc.) 133(8), 290\u2013295 (2009).","journal-title":"Med. Clin. (Barc.)"},{"key":"e_1_3_4_53_2","unstructured":"Estudio de evaluaci\u00f3n econ\u00f3mica de la accidentabilidad de las personas mayores en Espa\u00f1a. Madrid: Fundaci\u00f3n Mapfre Noviembre de 2012."},{"key":"e_1_3_4_54_2","first-page":"240","article-title":"Eficiencia de tratamientos oncol\u00f3gicos para tumores s\u00f3lidos en Espa\u00f1a","volume":"37","author":"Oyag\u00fcez I","year":"2013","unstructured":"Oyag\u00fcez I, Fr\u00edas C, Segu\u00ed MA Eficiencia de tratamientos oncol\u00f3gicos para tumores s\u00f3lidos en Espa\u00f1a. Farm. Hosp. 37, 240\u2013259 (2013).","journal-title":"Farm. Hosp."},{"key":"e_1_3_4_55_2","first-page":"325","article-title":"Cost\u2013effectiveness analysis of apixaban versus dabigatran for prevention of stroke in patients with non-valvular atrial fibrillation in Spain","volume":"16","author":"Beteg\u00f3n L","year":"2014","unstructured":"Beteg\u00f3n L, Canal C, Escolar G Cost\u2013effectiveness analysis of apixaban versus dabigatran for prevention of stroke in patients with non-valvular atrial fibrillation in Spain. Eur. J. Clin. Pharm. 16, 325\u2013338 (2014).","journal-title":"Eur. J. Clin. Pharm."},{"key":"e_1_3_4_56_2","article-title":"Abordaje pr\u00e1ctico de la patolog\u00eda urol\u00f3gica en Atenci\u00f3n Primaria. Algoritmos diagn\u00f3stico-terap\u00e9uticos","author":"S\u00e1nchez J","year":"2014","unstructured":"S\u00e1nchez J, Chantada V. Abordaje pr\u00e1ctico de la patolog\u00eda urol\u00f3gica en Atenci\u00f3n Primaria. Algoritmos diagn\u00f3stico-terap\u00e9uticos. Barcelona: EdikaMed (2014).","journal-title":"Barcelona: EdikaMed"},{"key":"e_1_3_4_57_2","first-page":"1","article-title":"Estimaci\u00f3n de los costes sanitarios relacionados con las fracturas osteopor\u00f3ticas en pacientes posmenop\u00e1usicas en Espa\u00f1a. PharmacoEcon","volume":"12","author":"Gonz\u00e1lez Y","year":"2015","unstructured":"Gonz\u00e1lez Y, Sicras A, Larra\u00ednzar R, Sorio F, Canals L, Liz\u00e1n L Estimaci\u00f3n de los costes sanitarios relacionados con las fracturas osteopor\u00f3ticas en pacientes posmenop\u00e1usicas en Espa\u00f1a. PharmacoEcon. Span. Res. Art. 12, 1\u20139 (2015).","journal-title":"Span. Res. Art."},{"key":"e_1_3_4_58_2","first-page":"87","article-title":"Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain","volume":"9","author":"Rejas Guti\u00e9rrez J","year":"2016","unstructured":"Rejas Guti\u00e9rrez J, Blanca Tamayo M, Gasc\u00f3n Barrachina J, Armada Pel\u00e1ez B. Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. Rev. Psiquiatr. Salud Ment. 9, 87\u201396 (2016).","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CEOR.S121093","article-title":"Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer","volume":"9","author":"Isla D","year":"2017","unstructured":"Isla D, De Castro J, Juan O Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEcon. Outcomes Res. 9, 31\u201338 (2017).","journal-title":"ClinicoEcon. Outcomes Res."},{"key":"e_1_3_4_60_2","unstructured":"Orden 727\/2017 de 7 de agosto del consejero de sanidad por la que se fijan los precios p\u00fablicos por la prestaci\u00f3n de los servicios y actividades de naturaleza sanitaria de la red de centros de la Comunidad de Madrid. BOCM N\u00b0 198 21 agosto 2017."},{"key":"e_1_3_4_61_2","unstructured":"Tarifas para facturaci\u00f3n de servicios sanitarios y docentes del Servicio vasco de salud para el a\u00f1o 2020. Servicio vasco de salud diciembre de 2019."},{"key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14737167.2020.1768850","article-title":"Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain","volume":"21","author":"Irimia P","year":"2021","unstructured":"Irimia P, Santos-Lasaosa S, Garc\u00eda Bujalance L, Ramos Pinazo L, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain. Expert Rev. Pharmacoecon. Outcomes Res. 21, 285\u2013297 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_4_63_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez-Bastida J","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias. Gac. Sanit. 24, 154\u2013170 (2010).","journal-title":"Gac. Sanit."},{"key":"e_1_3_4_64_2","first-page":"2","article-title":"Probabilistic analysis: sensitivity analysis or main result?","volume":"1","author":"Rubio-Terr\u00e9s C","year":"2016","unstructured":"Rubio-Terr\u00e9s C, Rubio-Rodr\u00edguez D. Probabilistic analysis: sensitivity analysis or main result? Pharmacoeconomics 1, 2 (2016).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_4_65_2","volume-title":"Decision Modelling for Health Economic Evaluation.","author":"Briggs A","year":"2007","unstructured":"Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press, UK (2007)."},{"key":"e_1_3_4_66_2","volume-title":"Applied Methods of Cost\u2013effectiveness Analysis in Healthcare.","author":"Gray AM","year":"2012","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost\u2013effectiveness Analysis in Healthcare. Oxford University Press, UK (2012)."},{"key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1186\/s12913-017-2807-x","article-title":"Impact on healthcare resource utilization of multiple sclerosis in Spain","volume":"17","author":"Sicras-Mainar A","year":"2017","unstructured":"Sicras-Mainar A, Ru\u00edz-Beato E, Navarro-Artieda R, Maurino J. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv. Res. 17, 854 (2017).","journal-title":"BMC Health Serv. Res."},{"key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A comparison of the EQ-5D and SF-6D across seven patient groups","volume":"13","author":"Brazier J","year":"2004","unstructured":"Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13, 873\u2013884 (2004).","journal-title":"Health Econ."},{"key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): concepts, measurement properties and applications","volume":"1","author":"Horsman J","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual. Life Outcomes 1, 54 (2003).","journal-title":"Health Qual. Life Outcomes"},{"key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7525-1-4","article-title":"What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D","volume":"1","author":"Walters SJ","year":"2003","unstructured":"Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual. Life Outcomes 1, 4 (2003).","journal-title":"Health Qual. Life Outcomes"},{"key":"e_1_3_4_71_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1524-4733.2007.00174.x","article-title":"Assessing differences in utility scores: a comparison of four widely used preference-based instruments","volume":"10","author":"Wee H-L","year":"2007","unstructured":"Wee H-L, Machin D, Loke W-C Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health 10, 256\u2013265 (2007).","journal-title":"Value Health"},{"key":"e_1_3_4_72_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and Cost\u2013effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator","volume":"14","author":"Palace J","year":"2015","unstructured":"Palace J, Duddy M, Bregenzer T Effectiveness and Cost\u2013effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 14, 497\u2013505 (2015).","journal-title":"Lancet Neurol."},{"key":"e_1_3_4_73_2","unstructured":"Tappenden P Chilcott J O'Hagan T Cost\u2013effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence (2001). Available from: www.academia.edu\/8908699\/Cost_effectiveness_of_beta_interferons_and_glatiramer_acetate_in_the_management_of_multiple_sclerosis (Accessed 31 January 2018)."},{"key":"e_1_3_4_74_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","article-title":"Cost\u2013effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population","volume":"12","author":"Tappenden P","year":"2009","unstructured":"Tappenden P, McCabe C, Chilcott J Cost\u2013effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 12, 657\u2013665 (2009).","journal-title":"Value Health"},{"key":"e_1_3_4_75_2","unstructured":"Peninsula Technology Assessment Group (PenTAG). The effectiveness and Cost\u2013effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen (2007). Available from: www.nice.org.uk\/guidance\/ta127\/resources\/multiple-sclerosis-natalizumabevaluation-report-evidence-review-group-report2 (Accessed 31 January 2018)."},{"key":"e_1_3_4_76_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost\u2013effectiveness analyzes of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK","volume":"26","author":"Gani R","year":"2008","unstructured":"Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost\u2013effectiveness analyzes of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 26, 617\u2013627 (2008).","journal-title":"Pharmacoeconomics"},{"issue":"7388","key":"e_1_3_4_77_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/bmj.326.7388.522","article-title":"Modelling the Cost\u2013effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis","volume":"326","author":"Chilcott J","year":"2003","unstructured":"Chilcott J, McCabe C, Tappenden P Modelling the Cost\u2013effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 326(7388), 522; discussion 522 (2003).","journal-title":"BMJ"},{"issue":"7","key":"e_1_3_4_78_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","article-title":"Cost\u2013effectiveness of cladribine tablets, alemtuzumab and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle R","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost\u2013effectiveness of cladribine tablets, alemtuzumab and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J. Med. Econ. 21(7), 676\u2013686 (2018).","journal-title":"J. Med. Econ."},{"key":"e_1_3_4_79_2","first-page":"189","article-title":"Economic evaluation of cladribine tablets in patients with high disease activity-relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia. Value Health Reg","volume":"25","author":"Bohlega S","year":"2021","unstructured":"Bohlega S, Elboghdady A, Al-Johani A Economic evaluation of cladribine tablets in patients with high disease activity-relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia. Value Health Reg. Issues 25, 189\u2013195 (2021).","journal-title":"Issues"},{"key":"e_1_3_4_80_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3111\/13696998.2015.1056794","article-title":"Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England","volume":"18","author":"Maruszczak MJ","year":"2015","unstructured":"Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. J. Med. Econ. 18, 874\u2013885 (2015).","journal-title":"J. Med. Econ."},{"key":"e_1_3_4_81_2","unstructured":"Hidalgo A Ivanova A Nozaya N. An\u00e1lisis del gasto asociado a los tratamientos de esclerosis m\u00faltiple en Espa\u00f1a durante el periodo 2004-2016. Available from: www.aes.es\/Jornadas2017\/pdfs\/posters\/Aes_2017_14_1.pdf (Accessed 6 June 2022)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2022-0193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T04:30:07Z","timestamp":1728793807000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.2217\/cer-2022-0193"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0193","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"e220193"}}